Cambridge Investment Research Advisors Inc. lifted its position in Becton, Dickinson and Company (NYSE:BDX) by 14.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,239 shares of the medical instruments supplier’s stock after buying an additional 2,058 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Becton, Dickinson and were worth $3,182,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its holdings in shares of Becton, Dickinson and by 1.1% in the third quarter. Russell Investments Group Ltd. now owns 814,791 shares of the medical instruments supplier’s stock worth $159,628,000 after buying an additional 8,621 shares in the last quarter. Stratos Wealth Partners LTD. purchased a new stake in shares of Becton, Dickinson and in the third quarter worth about $1,466,000. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of Becton, Dickinson and by 2.4% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 54,059 shares of the medical instruments supplier’s stock worth $10,593,000 after buying an additional 1,291 shares in the last quarter. Comerica Bank lifted its holdings in shares of Becton, Dickinson and by 4.5% in the third quarter. Comerica Bank now owns 92,076 shares of the medical instruments supplier’s stock worth $19,212,000 after buying an additional 3,985 shares in the last quarter. Finally, Bank of Stockton lifted its holdings in shares of Becton, Dickinson and by 7.6% in the third quarter. Bank of Stockton now owns 8,114 shares of the medical instruments supplier’s stock worth $1,589,000 after buying an additional 570 shares in the last quarter. 86.01% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have recently issued reports on BDX. Barclays PLC reissued an “equal weight” rating and issued a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. BidaskClub downgraded shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Zacks Investment Research raised shares of Becton, Dickinson and from a “sell” rating to a “hold” rating in a report on Friday, October 20th. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $213.47.

In other Becton, Dickinson and news, EVP Linda M. Tharby sold 4,695 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total transaction of $941,253.60. Following the transaction, the executive vice president now directly owns 18,670 shares in the company, valued at $3,742,961.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary M. Cohen sold 15,512 shares of the stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the transaction, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The disclosure for this sale can be found here. Insiders have sold 47,038 shares of company stock worth $9,480,225 over the last quarter. Company insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company (BDX) traded down $1.21 during mid-day trading on Friday, hitting $220.31. 718,967 shares of the company traded hands, compared to its average volume of 1,325,275. The company has a debt-to-equity ratio of 1.48, a quick ratio of 5.01 and a current ratio of 5.56. The company has a market capitalization of $50,410.00, a PE ratio of 23.23, a price-to-earnings-growth ratio of 1.73 and a beta of 1.04. Becton, Dickinson and Company has a one year low of $161.29 and a one year high of $225.23.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. During the same period last year, the business earned $2.12 earnings per share. The business’s quarterly revenue was down 2.0% on a year-over-year basis. equities analysts anticipate that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Cambridge Investment Research Advisors Inc. Acquires 2,058 Shares of Becton, Dickinson and Company (BDX)” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/cambridge-investment-research-advisors-inc-acquires-2058-shares-of-becton-dickinson-and-company-bdx/1711953.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.